Lilly Statement on sintilimab Oncologic Drugs Advisory Committee (ODAC) Meeting

While we are disappointed with the outcome of today’s ODAC as it relates to the investigational product sintilimab, we appreciated the opportunity to publicly discuss the application and broader issues related to single-country clinical trials. We had hoped that sintilimab could have played a